Chromocell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Cash & Equivalents	0.1	0.06	0	0
Cash & Cash Equivalents	0.1	0.06	0	0
Cash Growth	75.02%	-	-	-
Other Current Assets	0	0	0	0.07
Total Current Assets	0.1	0.06	0	0.07
Total Assets	0.1	0.06	0	0.07
Accounts Payable	4.62	2.99	2.58	3.41
Current Debt	1.27	0.54	0	0.24
Other Current Liabilities	0.65	0.23	0	0
Total Current Liabilities	6.54	3.76	2.58	3.65
Other Long-Term Liabilities	0	0	1.1	0
Total Long-Term Liabilities	0	0	1.1	0
Total Liabilities	6.54	3.76	3.68	3.65
Total Debt	1.27	0.54	0	0.24
Debt Growth	134.75%	-	-	-
Retained Earnings	-13.52	-6.14	-3.68	-3.58
Shareholders' Equity	-6.44	-3.71	-3.68	-3.58
Net Cash / Debt	-1.17	-0.49	0	-0.24
Net Cash Per Share	-0.92	-1.11	-	-
Working Capital	-6.44	-3.71	-2.58	-3.58
Book Value Per Share	-5.05	-8.52	-3.31	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).